Trial Profile
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2020
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Exenatide; Glibenclamide; Glimepiride; Glipizide; Linagliptin; Metformin; Pioglitazone; Saxagliptin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 01 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2015 New trial record